Publication at Third Faculty of Medicine |
2016
Abstract
Pembrolizumab is a PD-1 inhibitor which is showing significant clinical response rate and overal survival in patients with metastatic malignant melanoma. In the article, indications, efficacy and adverse events are discussed.